{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:44:56Z","timestamp":1778161496089,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04173-0","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:13:39Z","timestamp":1748567619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-xia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-yang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"4173_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"4173_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466\u201378.","journal-title":"Nat Rev Nephrol"},{"key":"4173_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199\u2013205.","journal-title":"Kidney Int."},{"key":"4173_CR4","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2021; 100: S1\u2013276."},{"key":"4173_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1056\/NEJM198404123101503","volume":"310","author":"C Ponticelli","year":"1984","unstructured":"Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310:946\u201350.","journal-title":"N Engl J Med"},{"key":"4173_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.08880813","volume":"9","author":"JA van den Brand","year":"2014","unstructured":"van den Brand JA, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9:1066\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4173_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28:348\u201358.","journal-title":"J Am Soc Nephrol"},{"key":"4173_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36\u201346.","journal-title":"N Engl J Med"},{"key":"4173_CR9","first-page":"1130","volume":"47","author":"DC Cattran","year":"1995","unstructured":"Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group Kidney Int. 1995;47:1130\u20135.","journal-title":"Canadian Glomerulonephritis Study Group Kidney Int"},{"key":"4173_CR10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59:1484\u201390.","journal-title":"Kidney Int"},{"key":"4173_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Ju\u00e1rez GF, Lu\u00f1o J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924\u201330.","journal-title":"Kidney Int"},{"key":"4173_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","volume":"2","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran R, Yadav AK, Kumar V, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2:610\u20136.","journal-title":"Kidney Int Rep"},{"key":"4173_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ajhp\/57.5.437","volume":"57","author":"EM Vasquez","year":"2000","unstructured":"Vasquez EM. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm. 2000;57:437\u201348.","journal-title":"Am J Health Syst Pharm"},{"key":"4173_CR14","doi-asserted-by":"publisher","first-page":"9231","DOI":"10.1073\/pnas.87.23.9231","volume":"87","author":"BE Bierer","year":"1990","unstructured":"Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87:9231\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"4173_CR15","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1681\/ASN.2004030180","volume":"16","author":"RGB Bonegio","year":"2005","unstructured":"Bonegio RGB, Fuhro R, Wang ZY, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol. 2005;16(7):2063\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"4173_CR16","doi-asserted-by":"publisher","first-page":"941893","DOI":"10.1155\/2013\/941893","volume":"2013","author":"S Stratakis","year":"2013","unstructured":"Stratakis S, Stylianou K, Petrakis I, et al. Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy. Clin Dev Immunol. 2013;2013:941893.","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"4173_CR17","doi-asserted-by":"publisher","first-page":"e13463","DOI":"10.1111\/ctr.13463","volume":"33","author":"AF Hamdy","year":"2019","unstructured":"Hamdy AF, Elhadedy MA, Donia AF, et al. Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience. Clin Transplant. 2019;33(2):e13463.","journal-title":"Clin Transplant"},{"key":"4173_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ki.2010.457","volume":"79","author":"TB Huber","year":"2011","unstructured":"Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int. 2011;79:502\u201311.","journal-title":"Kidney Int"},{"issue":"10","key":"4173_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrneph.2016.108","volume":"12","author":"D Fantus","year":"2016","unstructured":"Fantus D, Rogers NM, Grahammer F, et al. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol. 2016;12(10):587\u2013609.","journal-title":"Nat Rev Nephrol"},{"key":"4173_CR20","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/TP.0000000000001729","volume":"102","author":"MKM Ma","year":"2018","unstructured":"Ma MKM, Yung S, Chan TM. mTOR inhibition and kidney diseases. Transplantation. 2018;102:S32\u201340.","journal-title":"Transplantation"},{"issue":"10126","key":"4173_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"ZW Lai","year":"2018","unstructured":"Lai ZW, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet. 2018;391(10126):1186\u201396.","journal-title":"Lancet"},{"issue":"12","key":"4173_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3899\/jrheum.180507","volume":"45","author":"DYH Yap","year":"2018","unstructured":"Yap DYH, Tang C, Chan GCW, et al. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. J Rheumatol. 2018;45(12):1663\u201370.","journal-title":"J Rheumatol"},{"issue":"1","key":"4173_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","volume":"92","author":"M Rosenzwajg","year":"2017","unstructured":"Rosenzwajg M, Languille E, Debiec H, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int. 2017;92(1):227\u201337.","journal-title":"Kidney Int"},{"issue":"6","key":"4173_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ekir.2020.03.023","volume":"5","author":"R Ramachandran","year":"2020","unstructured":"Ramachandran R, Kaundal U, Girimaji N, et al. Regulatory B Cells Are Reduced and Correlate with Disease Activity in Primary Membranous Nephropathy. Kidney Int Rep. 2020;5(6):872\u20138.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"4173_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.kint.2022.11.021","volume":"103","author":"XD Zhang","year":"2023","unstructured":"Zhang XD, Lin CX, Cui Z, et al. Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy. Kidney Int. 2023;103(3):580\u201392.","journal-title":"Kidney Int"},{"issue":"7","key":"4173_CR26","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1681\/ASN.2016050519","volume":"28","author":"S Zschiedrich","year":"2017","unstructured":"Zschiedrich S, Bork T, Liang W, et al. Targeting mTOR Signaling Can Prevent the Progression of FSGS. J Am Soc Nephrol. 2017;28(7):2144\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"4173_CR27","doi-asserted-by":"crossref","unstructured":"Cruzado JM, Poveda R, Iberno\u00b4n M, et al. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant. 2011; 26: 3596\u20133602","DOI":"10.1093\/ndt\/gfr072"},{"issue":"5","key":"4173_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/ndt\/gfh752","volume":"20","author":"P Patel","year":"2005","unstructured":"Patel P, Pal S, Ashley C, et al. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol Dial Transplant. 2005;20(5):985\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"4173_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/01.TP.0000128837.07640.AE","volume":"78","author":"D Ninova","year":"2004","unstructured":"Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor beta-1 and alpha smooth muscle actin. Transplantation. 2004;78:338\u201344.","journal-title":"Transplantation"},{"issue":"1","key":"4173_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2215\/CJN.00120605","volume":"1","author":"JA Tumlin","year":"2006","unstructured":"Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2006;1(1):109\u201316.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4173_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/0886022X.2017.1373130","volume":"39","author":"X Yu","year":"2017","unstructured":"Yu X, Ruan L, Qu Z, et al. Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. Ren Fail. 2017;39(1):688\u201397.","journal-title":"Ren Fail"},{"issue":"6","key":"4173_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/MAJ.0b013e3181d9f00b","volume":"339","author":"J Li","year":"2010","unstructured":"Li J, Zhang YM, Qu Z, et al. Low-dose cyclosporine treatment in Chinese nephrotic patients with idiopathic membranous nephropathy: An uncontrolled study with prospective follow-up. Am J Med Sci. 2010;339(6):532\u20136.","journal-title":"Am J Med Sci"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04173-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:13:43Z","timestamp":1748567623000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04173-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04173-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol was designed by the principal investigators and approved by an independent ethics committee (approval number: 2017[1346]). The study was conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent prior to enrollment. The trial was registered with the Chinese Clinical Trial Registry (ChiCTR-INR-17012212).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including images, videos, or case details) that would require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}